The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis

Int Immunopharmacol. 2018 Jun:59:227-232. doi: 10.1016/j.intimp.2018.04.019. Epub 2018 Apr 14.

Abstract

Objective: Dickkopf-1 (DKK-1) is an endogenous inhibitor of canonical Wnt pathway that was implicated in the pathogenesis of rheumatoid arthritis (RA), but the serum levels of DKK-1 in RA were inconsistent among studies. Therefore, we conducted a meta-analysis to systematically evaluate the relationship between serum DKK-1 levels and RA.

Methods: PubMed, Web of Science and Cochrane Library were comprehensively retrieved till 1 January 2018 for pertinent studies. The pooled standard mean differences (SMDs) of serum DKK-1 levels were calculated according to the random effects model.

Results: Nine original studies containing 1305 RA patients and 504 healthy controls were included in the meta-analysis. The pooled SMD of serum DKK-1 between RA patients and healthy controls was 0.79 (95% CI = 0.11 to 1.48, Z = 2.28 and P = 0.023), indicating a significantly higher serum level of DKK-1 in RA patients.

Conclusion: Serum level of DKK-1 is elevated in patients with RA compared to healthy controls, suggesting an important role of DKK-1 in the pathogenesis and treatment of RA.

Keywords: Dickkopf-1; Rheumatoid arthritis.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / blood*
  • Humans
  • Intercellular Signaling Peptides and Proteins / blood*

Substances

  • DKK1 protein, human
  • Intercellular Signaling Peptides and Proteins